Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Schlichting

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
ACR Open Rheumatology|December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of BaricitinibJanet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
American Journal of Obstetrics and Gynecology|June 16, 2024
A pilot randomized trial of automatic, artificial intelligence-based vs manual, electronic medical record-based remote postpartum blood pressure monitoringAdam K Lewkowitz, Rackeem Baker, Lauren E Schlichting, et al.
The Journal of Animal Ecology|June 28, 2024
Estimating encounter-habitat relationships with scale-integrated resource selection functionsMichael E Egan, Nicole T Gorman, Storm Crews, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 29, 2016
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid ArthritisJoel M Kremer, Mark C Genovese, Edward Keystone, et al.
Annals of the Rheumatic Diseases|November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2006
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled studyJ Geisler, P E Lønning, L E Krag, et al.
Rheumatology (Oxford, England)|February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisMark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated AnalysisYoshiya Tanaka, Iain B McInnes, Peter C Taylor, et al.
RMD Open|May 17, 2018
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugsDesirée van der Heijde, Maxime Dougados, Ying-Chou Chen, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
ACR Open Rheumatology|December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of BaricitinibJanet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
American Journal of Obstetrics and Gynecology|June 16, 2024
A pilot randomized trial of automatic, artificial intelligence-based vs manual, electronic medical record-based remote postpartum blood pressure monitoringAdam K Lewkowitz, Rackeem Baker, Lauren E Schlichting, et al.
The Journal of Animal Ecology|June 28, 2024
Estimating encounter-habitat relationships with scale-integrated resource selection functionsMichael E Egan, Nicole T Gorman, Storm Crews, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 29, 2016
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid ArthritisJoel M Kremer, Mark C Genovese, Edward Keystone, et al.
Annals of the Rheumatic Diseases|November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2006
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled studyJ Geisler, P E Lønning, L E Krag, et al.
Rheumatology (Oxford, England)|February 8, 2018
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritisMark C Genovese, Joel M Kremer, Cynthia E Kartman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated AnalysisYoshiya Tanaka, Iain B McInnes, Peter C Taylor, et al.
RMD Open|May 17, 2018
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugsDesirée van der Heijde, Maxime Dougados, Ying-Chou Chen, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Pageof 11